ENTA - CIK 0001177648
ENANTA PHARMACEUTICALS INC trades as ENTA. In its fiscal 2025 annual report the company posted revenue of $65.32M, down 3.4% from the prior year and net income of -$81.89M. This page tracks ENANTA PHARMACEUTICALS INC through 822 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years ENANTA PHARMACEUTICALS INC's revenue declined from $88.27M to $65.32M, a compound annual decline rate of 3.3%. Net profit margin compressed from 24.5% to -125.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Employee stock plan | S-8 | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-11 |
| Major company event | 8-K | 2026-03-26 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Insider trade | 4 | 2026-03-13 |
| Insider trade | 4 | 2026-03-13 |
| Insider trade | 4 | 2026-03-13 |
The largest companies sharing ENANTA PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).
ENANTA PHARMACEUTICALS INC reported revenue of $65.32M for fiscal year 2025, a decrease of 3.4% year over year.
In its latest fiscal year ENANTA PHARMACEUTICALS INC reported a net loss of $81.89M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.